Predicted protein targets (top 13)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | CYP1A2 | P05177 | 1/20 | 0.34 |
| ▸ | GPR3 | P46089 | 1/20 | 0.34 |
| ▸ | PTPN7 | P35236 | 1/20 | 0.33 |
| ▸ | DUSP3 | P51452 | 1/20 | 0.33 |
| ▸ | PTPN12 | Q05209 | 1/20 | 0.33 |
| ▸ | PTPN22 | Q9Y2R2 | 1/20 | 0.33 |
| ▸ | ALDH1A1 | P00352 | 1/20 | 0.31 |
| ▸ | MAPT | P10636 | 1/20 | 0.31 |
| ▸ | HPGD | P15428 | 1/20 | 0.31 |
| ▸ | RAB9A | P51151 | 1/20 | 0.31 |
| ▸ | SMN1; SMN2 | Q16637 | 1/20 | 0.31 |
| ▸ | ELANE | P08246 | 1/20 | 0.30 |
| ▸ | PTGIR | P43119 | 1/20 | 0.30 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL23370908 | 0.99 | CYP1A2 (0.35) | CYP1A2GPR3PTPN7DUSP3PTPN12 | |
| SCHEMBL22739618 | 0.96 | CYP1A2 (0.34) | CYP1A2GPR3PTPN7DUSP3PTPN12 | |
| SCHEMBL22740294 | 0.93 | GPR3 (0.33) | CYP1A2GPR3PTPN7DUSP3PTPN12 | |
| SCHEMBL22741389 | 0.93 | ALDH1A1 (0.36) | GPR3ALDH1A1MAPTHPGDRAB9A | |
| SCHEMBL22739915 | 0.92 | ESR2 (0.33) | CYP1A2GPR3PTPN7DUSP3PTPN12 | |
| SCHEMBL24000698 | 0.91 | CYP1A2 (0.35) | CYP1A2GPR3PTPN7DUSP3PTPN12 | |
| SCHEMBL24000248 | 0.91 | CYP1A2 (0.35) | CYP1A2GPR3PTPN7DUSP3PTPN12 | |
| SCHEMBL24527253 | 0.90 | CASP3 (0.32) | CYP1A2GPR3PTPN7DUSP3PTPN12 | |
| SCHEMBL22741487 | 0.89 | ESR2 (0.31) | CYP1A2 | |
| SCHEMBL24000689 | 0.89 | GPR3 (0.33) | CYP1A2GPR3PTPN7DUSP3PTPN12 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 1 patent. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20200377513-A1 | NOVEL COMPOUND AND ORGANIC ELECTROLUMINESCENCE DEVICE | IDEMITSU KOSAN CO.,LTD. (JP) | 2020-12-03 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20200377513-A1 | NOVEL COMPOUND AND ORGANIC ELECTROLUMINESCENCE DEVICE | PIEZO1, TMEM109, LEF1 | CYP1A2 1206/4885GPR3 3570/4885PTPN7 4715/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.